2mo
Share
1mo
Use of intravenous lipid emulsions in drug-induced toxicities: a 2025 narrative review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41247632/
Intravenous lipid emulsions (ILE) were first proposed in 1998 as a treatment for bupivacaine-induced cardiac arrest. Since then, their use has expanded to include poisonings by various lipophilic drugs such...
ILEs treat lipophilic drug toxicities through lipid sink, shuttle, and cardiotonic mechanisms; benefits shown in select poisonings, but mortality impact, optimal dosing, and indications remain uncertain, requiring higher-quality evidence.
Share
2mo
Evaluating the impact of testosterone replacement therapy on carotid atherosclerosis: a systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39183456/
Aim: This meta-analysis investigates the association between testosterone replacement therapy [TRT] and carotid artery atherosclerosis. Methods: 3 databases were searched for studies up to June 2023 per the PRISMA guidelines....
Testosterone therapy shows no association with carotid atherosclerosis or lipid/inflammatory markers, though it raises testosterone levels, suggesting safe use in hypogonadal men without increasing CIMT risk.
Share
2mo
Patient Background: A 79-year-old woman presented with persistent hypophosphatemia (serum phosphorus 0.8 mg/dL) and multiple stress fractures involving the ribs, spine, and pelvis, consistent with osteomalacia. Her medical history included type 2 diabetes mellitus, hypertension, obesity, osteoarthritis, and anxiety disorder.
Assessment and Diagnosis: Initial evaluation revealed severe hypophosphatemia (0.8 mg/dL; NR: 2.5–4.5 mg/dL), elevated parathyroid hormone (PTH, 169 pg/mL; NR: 10–65 pg/mL), and normal serum calcium levels. Despite vitamin D supplementation, hypophosphatemia persisted (1.7 mg/dL in 2023), and hypercalcemia developed later (10.9 mg/dL; NR: 8.5–10.2 mg/dL). Renal studies showed phosphate wasting (tubular reabsorption of phosphate [TRP] 56.2%) and elevated fibroblast growth factor 23 (FGF-23, 1694 kRU/L). In 2024, ^18F-fluorocholine PET-CT imaging identified two right parathyroid adenomas, confirming a diagnosis of primary hyperparathyroidism (PHPT).
- How can chronic hypophosphatemia signal early-stage PHPT?
- Why is postoperative monitoring vital in PHPT care?
Share
2mo
Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37610687/
Currently, available evidence consistently demonstrates and is in good agreement that, in general, the LDL-C-lowering effect of PCSK9 inhibitors is similar across genotypes, except for compound heterozygous and homozygous familial...
Genetic background slightly affects PCSK9 inhibitors’ LDL-C lowering in familial hypercholesterolemia, with reduced response in compound heterozygous and homozygous cases; clinical factors remain key for management.
Share